UroGen Pharma Ltd. (URGN) stock
URGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$29.87+1.77 (+6.30%)
Close on Nov 17, 2026Market cap $1.46BP/E –Yield –
UroGen Pharma operating margin
Operating margin is operating income as a percentage of revenue.
UroGen Pharma's operating margin for the twelve months ending Jun 30, 2026 was -35.3%. For fiscal 2025 it was -113.7%, against -107.1% the year before. The highest annual figure on record is 4.6% in fiscal 2016.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -113.7% | −6.7 |
| FY2024 | Dec 31, 2024 | -107.1% | −27.8 |
| FY2023 | Dec 31, 2023 | -79.2% | +43.6 |
| FY2022 | Dec 31, 2022 | -122.8% | +69.3 |
| FY2021 | Dec 31, 2021 | -192.1% | +882.0 |
| FY2020 | Dec 31, 2020 | -1074.2% | +607137.0 |
| FY2019 | Dec 31, 2019 | -608211.1% | −601368.9 |
| FY2018 | Dec 31, 2018 | -6842.2% | −6597.7 |
| FY2017 | Dec 31, 2017 | -244.5% | −249.1 |
| FY2016 | Dec 31, 2016 | 4.6% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 0.2% | +171.3 |
| Q1 FY2026 | Mar 31, 2026 | -39.8% | +142.5 |
| Q4 FY2025 | Dec 31, 2025 | -50.5% | +62.1 |
| Q3 FY2025 | Sep 30, 2025 | -99.7% | −30.0 |
| Q2 FY2025 | Jun 30, 2025 | -171.2% | −52.9 |
| Q1 FY2025 | Mar 31, 2025 | -182.3% | −45.2 |
| Q4 FY2024 | Dec 31, 2024 | -112.6% | −50.5 |
| Q3 FY2024 | Sep 30, 2024 | -69.6% | −4.9 |
| Q2 FY2024 | Jun 30, 2024 | -118.3% | −45.5 |
| Q1 FY2024 | Mar 31, 2024 | -137.1% | −8.8 |
| Q4 FY2023 | Dec 31, 2023 | -62.1% | +50.0 |
| Q3 FY2023 | Sep 30, 2023 | -64.7% | +47.6 |
| Q2 FY2023 | Jun 30, 2023 | -72.8% | +39.9 |
| Q1 FY2023 | Mar 31, 2023 | -128.2% | +33.6 |
| Q4 FY2022 | Dec 31, 2022 | -112.1% | +11.0 |
| Q3 FY2022 | Sep 30, 2022 | -112.4% | +94.1 |
| Q2 FY2022 | Jun 30, 2022 | -112.7% | +62.4 |
| Q1 FY2022 | Mar 31, 2022 | -161.9% | +187.0 |
| Q4 FY2021 | Dec 31, 2021 | -123.1% | +219.0 |
| Q3 FY2021 | Sep 30, 2021 | -206.5% | +635.0 |
| Q2 FY2021 | Jun 30, 2021 | -175.1% | +8373.3 |
| Q1 FY2021 | Mar 31, 2021 | -348.9% | +131612.2 |
| Q4 FY2020 | Dec 31, 2020 | -342.1% | +7109.8 |
| Q3 FY2020 | Sep 30, 2020 | -841.5% | +4222.8 |
| Q2 FY2020 | Jun 30, 2020 | -8548.4% | −5712.6 |
| Q2 FY2019 | Jun 30, 2019 | -131961.1% | −128854.7 |
| Q3 FY2018 | Sep 30, 2018 | -7451.9% | −7448.1 |
| Q2 FY2018 | Jun 30, 2018 | -5064.3% | +13556.8 |
| Q1 FY2018 | Mar 31, 2018 | -2835.8% | – |
| Q4 FY2017 | Dec 31, 2017 | -3106.4% | – |
| Q3 FY2017 | Sep 30, 2017 | -3.9% | – |
| Q1 FY2017 | Mar 31, 2017 | -18621.1% | – |
See a number that looks wrong?